Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-SATO in paediatric neuroblastoma patients (GAP NBL study)
2024-513843-10-00Phase 2Suspended
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Oct 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga-SATO in neuroblastoma, sponsored by Princess Máxima Center for Pediatric Oncology. Started Oct 2024; status: suspended.
02
Drugs
68Ga-SATO
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2024-513843-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513843-10-00.